Trending Topic

2 mins

Trending Topic

Developed by Touch
Mark CompleteCompleted
BookmarkBookmarked

From advances in targeted therapies to the integration of AI and steps towards precision medicine, 2024 brought many exciting developments in the field. With 2025 now unfolding, many of these are likely to continue gaining momentum and potentially redefine patient care. In this latest edition of touchREVIEWS in RMD, we’re excited to present a collection […]

Gout

An Introduction to Gout

Gout, the most common inflammatory arthritis worldwide, is characterized by intense pain and impaired quality of life. Management strategies include weight management, increasing exercise and reducing alcohol consumption to reduce uric acid levels, as well as treatment with xanthine oxidase inhibitors. Other urate-lowering strategies include the selective uric acid reabsorption inhibitors lesinurad and arhalofenate. An acute attack of gout is likely to require treatment with a nonsteroidal anti-inflammatory drug (NSAID) or colchicine. Emerging anti-inflammatory strategies involving targeted anti-interleukin (IL) therapy appear effective in reducing the pain of acute attacks as well as preventing recurrent attacks. 

Browse our selection of video highlights and short articles from the conference hub, providing insights into the latest updates from major conferences and a selection of peer-reviewed articles from the journal portfolio.

Our supporting partners do not constitute an endorsement of the content on this page.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

Physician burnout is at a critical point. In this episode, Nicky speaks with Dr Alfred Atanda about why so many physicians are burning out and what can be done to change the trend. From personal experience to system-wide solutions, Dr Atanda shares valuable insights on improving physician well-being and building a more effective healthcare culture.

Mark CompleteCompleted
BookmarkBookmarked

What if your medical degree could launch more than a clinical career? In this candid and compelling read, Dr Jon Edelson shares his lessons for early-career doctors ready to think beyond the bedside and explore the business of medicine.

touchVisionary Voices
Mark CompleteCompleted
BookmarkBookmarked

In this episode, we explore the future of continuing medical education (CME) with the team behind touchIME. Hannah Fisher and Matthew Goodwin share insights into global and US trends, the importance of patient inclusivity and how educational outcomes are evolving to better measure the direct impact of learning on clinical practice and patient care.

Developed by Touch
Coverage from: ACR Highlights

Pegloticase is a urate-lowering therapy that is approved for the treatment of gout. touchIMMUNOLOGY were delighted to speak with Prof. Michael Pillinger (NYU Grossman School of Medicine, New York, NY, USA) to discuss whether urate lowering therapy impacted the neutrophil-to-lymphocyte ...

Developed by Touch
Coverage from: ACR Highlights

The neutrophil-to-lymphocyte ratio (NLR) is a biomarker that is increased in patients with active gout. touchIMMUNOLOGY were delighted to speak with Prof. Michael Pillinger (NYU Grossman School of Medicine, New York, NY, USA) to discuss the pathophysiology of gout flares ...

Mark CompleteCompleted
BookmarkBookmarked

Gout is a systemic and underserved disease. Many primary care physicians are treating gout as an episodic disease, providing therapies for only the acute attack.1 As a result of this, many patients with gout are languishing without even being given ...

Developed by Touch
Coverage from: EULAR Highlights

The FDA has recently approved pegloticase injection co-administered with methotrexate in uncontrolled gout following the findings from the MIRROR randomized clinical trial presented at EULAR 2022. touchIMMUNOLOGY were delighted to speak with Dr. John K. Botson (Orthopedic Physicians Alaska, Anchorage, AK, ...

Coverage from: ACR Highlights

It was a pleasure to meet with Professor Robert Terkeltaub (UC San Diego, San Diego, California, USA) to discuss the efficacy and safety findings from the phase 2 study of tigulixostat in gout with hyperuricemia (NCT03934099). This information is brought to ...

Coverage from: ACR Highlights

In Part 2, Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) discusses further how the results of the FAST study compared to another study, the CARES trial, which also investigated the cardiovascular risks associated with these two treatments.  The late-breaking abstract ...

Coverage from: ACR Highlights

Following concerns related to the cardiovascular safety of febuxostat, the European Medicines Agency recommended a post-licensing study assessing the cardiovascular safety of febuxostat compared with allopurinol. Here we talk to Thomas MacDonald (University of Dundee, Dundee, Scotland, UK) about the ...

Load More...
Close Popup